Blood coagulation, fibrinolysis, and markers of endothelial dysfunction in systemic sclerosis

Seminars in Arthritis and Rheumatism

Volumn 32, Issue 5, 2003, Pages 285-295

  Cerinic, Marco Matucci ^a   Valentini, G ^b   Sorano, G G ^c   D'Angelo, S ^b   Cuomo, G ^b   Fenu, L ^c   Generini, S ^a   Cinotti, S ^a   Morfini, M ^a   Pignone, A ^a   Guiducci, S ^a   Del Rosso, A ^a   Kalfin, R ^d   Das, D ^d   Marongiu, F ^c  

^a UNIVERSITY OF FLORENCE   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c UNIVERSITY OF CAGLIARI   (Italy)

^d UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

Author keywords

Adhesion molecules; Coagulation; Endothelial injury; Fibrinolysis; Systemic sclerosis

Indexed keywords

D DIMER; DERMATAN SULFATE; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; INTERCELLULAR ADHESION MOLECULE 1; LIPOPROTEIN A; PLASMINOGEN ACTIVATOR INHIBITOR; THROMBIN ANTITHROMBIN COMPLEX; THROMBOMODULIN; TISSUE PLASMINOGEN ACTIVATOR; VASCULAR CELL ADHESION MOLECULE 1; VON WILLEBRAND FACTOR;

ADULT; ARTICLE; BLOOD CLOTTING; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE MARKER; ENDOTHELIUM INJURY; EVALUATION; FEMALE; FIBRINOLYSIS; FORCED EXPIRATORY VOLUME; HUMAN; MALE; PLASMA; PRIORITY JOURNAL; SKIN; SYSTEMIC SCLEROSIS; VASCULAR PATENCY; VITAL CAPACITY;

EID: 0344511824     PISSN: 00490172     EISSN: None     Source Type: Journal    
DOI: 10.1053/sarh.2002.50011     Document Type: Article

References (74)

1. Matucci-Cerinic M, Kahaleh BM, Leroy EC. Vascular involvement: pathogenesis. In: Systemic Sclerosis, Furst D, Clements P, eds. New York, Lea & Febiger 1995;153-66.
2. Furey NL, Schmid FR, Kwan HC, Friederici HH. Arterial thrombosis in scleroderma. Br J Dermatol 1975;93:683-93.
3. Holland CD, Jayson MIV. Venous blood fibrinolysis and fibrinolytic potential in primary Raynaud's phenomenon and systemic sclerosis associated with Raynaud's phenomenon. In: Progressive Systemic Sclerosis, Black CM, Myers AR, eds., New York, Gower 1985;267-73.
4. Matucci-Cerinic M, Lotti T, Lombardi A, Pignone A, lannone F, Cinotti S, et al. Cutaneous and plasma fibrinolytic activity in systemic sclerosis: evidence of a normal plasminogen activation. Int J Dermatol 1990;29:644-8.
5. Lotti T, Matucci-Cerinic M, Marmugi D, Fabbri P. Cutaneous fibrinolytic activity in scleroderma. Clin Exp Rheumatol 1985;3:249-53.
6. Falanga V, Kruskal JB, Franks JJ. Fibrin and fibrinogen related antigens in systemic sclerosis (scleroderma). J Am Acad Dermatol 1991;25:771-5.
7. Herrick AL, Illingworth K, Blann A, Hay CRM, Hollis S, Jayson MIV. von Willebrand factor, thrombomodulin, thromboxane, thromboglobulin and markers of fibrinolysis in primary Raynaud's phenomenon and systemic sclerosis. Ann Rheum Dis 1996;55:122-7.
8. Ames PRJ, Lupoli S, Alves J, Atsumi T, Edwards C, Iannaccone L, et al. The coagulation/fibrinolysis balance in systemic sclerosis: evidence for a haematological stress sindrome. Br J Rheumatol 1997;36:1045-50.
9. LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger M, et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988; 15:202-5.
10. Kluft C, Verheijen JH. Leiden fibrinolysis working party: blood collection and handling procedures for assessment of tissue-type plasminogen activator and plasminogen activator inhibitor 1. Fibrinolysis 1990;4(suppl 2):155-61.
11. Mannucci PM, Giangrande PL. Detection of the prothrombotic state due to procoagulant imbalance. Eur J Haemost 1992;48:65-9.
12. Pelzer H, Scwarz A, Heimburger N. Determination of human thrombin-antithrombin III complex in plasma with an enzyme-linked immunosorbent assay. Thromb Haemost 1988; 59:101-6.
13. Pelzer H, Scwarz A, Stuber W. Determination of human prothrombin activation fragment 1+2 and TAT in plasma with antibody against a synthetic peptide. Thromb Haemost 1991; 65:153-9.
14. Tolefsen DM, Pestka CA, Monafo WF. Activation of heparin cofactor II by dermatan sulphate. J Biol Chem 1983; 258:6713-6.
15. Dupoy D, Sie P, Dol F, Boneu A. A simple method to measure dermatan sulphate at sub-microgram conceentration in plasma. Thromb Haemost 1988;60:236-9.
16. Takahashi H, Ito S, Hanano M, Wada K, Niwano H, Seki Y, et al. Circulating thrombomodulin as a novel endothelial cell marker: comparison of its behaviour with von Willebrand factor and tissue type plasminogen activator. Am J Hematol 1992;41:32-9.
17. Kahaleh BM, Osborn I, LeRoy CM. Increased factor VIII/von Willebrand factor antigen and von Willebrand factor activity in scleroderma and in Raynaud's phenomenon. Ann Int Med 1981;94:482-4.
18. Matucci-Cerinic M, Martinez Lavin M, Rojo F, Fonseca C, Kahaleh B. von Willebrand Factor levels in hypertrophic osteoarthropathy. J Rheumatol 1992;19:465-9.
19. Zimmerman TS, Dent JA, Ruggeri ZM, Nannini LH. Subunit composition of plasma von Willebrand factor. Cleavage is present in normal individuals, increased in IIA and IIB von Willebrand disease, but minimal in variants with aberrant structure of individual oligomers (types IIC, IID, and IIE). J Clin Invest 1986;77:947-51.
20. Wejkum L, Rosen S, Soerskog L, Brandt B, Chmielewska J. Blood sampling and determination of of tissue plasminogen activator activity with COA-SET t-PA. Fibrinolysis 1990;4(suppl 2):152-4.
21. Weikum L, Chmielewska J. A new adaptation of COA-SET PAI measurement of low inhibitor concentration in plasma. Fibrinolysis 1990;4(suppl 2):130-2.
22. Whitaker A, Elms M, Masci P. Measurement of crosslinked fibrin derivatives in plasma: an immunoassay using monoclonal antibodies. J Clin Pathol 1984;37:882-7.
23. Pignone A, Scaletti C, Matucci-Cerinic M, Vazquez-Abad D, Falcini F, Generini S, et al. Anti-endothelial cell antibodies in systemic sclerosis: significant association with vascular involvement and alveolo-capillary impairment. Clin Exp Rheumatol 1998;16:527-32.
24. Kahaleh MB, Sultany GL, Smith EA, Huffstutter JE, Loadholt CB, LeRoy EC. A modified scleroderma skin scoring method. Clin Exp Rheumatol 1986;4:367-9.
25. Lee P, Norman CS, Sukenik S, Alderdice CA. The clinical significance of coagulation abnormalities in systemic sclerosis (scleroderma). J Rheumatol 1985;12:514-7.
26. Maeda M, Kachi H, Mori S. Plasma levels of molecular markers of blood coagulation and fibrinolysis in progressive systemic sclerosis. J Dermatol Sci 1996;1:223-7.
27. Veale DJ, Collidge TA, Belch JJ. Increased prevalence of symptomatic macrovascular disease in systemic sclerosis. Ann Rheum Dis 1995;54:853-5.
28. Rath M, Niendorf A, Reblin T, Dietel M, Krebber HJ, Beisiegl U. Detection and quantitation of lipoprotein (a) in the arterial wall of 107 coronary artery patients. Arteriosclerosis 1989;9:579-85.
29. Asanuma Y, Kawa I, Aoshima H, Kaburaki J, Mizushima Y. Serum lipoprotein (a) and apolipoprotein (a) phenotypes in patients with rheumatoid arthritis. Arthritis Rheum 1999;42:443-7.
30. Borba EF, Santos RD, Bonfa E, Vinagre CG, Pileggi FJ, Maranhao RC, et al. Lipoprotein (a) levels in systemic lupus erythematosus. J Rheumatol 1994;21:220-3.
31. Atsumi A, Khamashta MA, Andujar CA, Leandro MJ, Amengual O, Ames PRJ, et al. Elevated plasma lipoprotein (a) level and its association with impaired fibrinolysis in patients with antiphospholipid syndrome. J Rheumatol 1998;25:69-73.
32. Smith EB, Cochran S. Factors influencing the accumulation in fibrous plaques of lipid derived from low density lipoprotein (a). Atherosclerosis 1990;84:173-9.
33. Edelber JM, Pizzo SV. Lipoprotein (a) inhibits plasminogen activation in a template-dependent manner. Blood Coagulat Fibrinol 1991;2:759-64.
34. Etigin OR, Hajjar DP, Hajjar KA, Harpel PC, Nachman RL. Lipoproten (a) regulates plasminogen activator inhibitor in endothelial cells. J Biol Chem 1991;266:2459-65.
35. Okawa-Takatsuji M, Aotsuka S, Sumiya M, Ohta H, Kawakami M, Sakurabayashi I. Clinical significance of the serum lipoprotein (a) level in patients with systemic lupus erythematosus: its elevation during disease flare. Clin Exp Rheumatol 1996;14:531-6.
36. Ishii H, Ichiyama H, Kazama M. Soluble thrombomodulin antigen in conditioned medium is increased by damage of endothelial cells. Thromb Haemost 1991;65:618-23.
37. Haznedaroglu IC, Ozdemir O, Ozcebe O, Dundar SV, Kirazli S. Circulating thrombomodulin as a clue of endothelial damage in Behcet's disease. Thrombosis Haemost 1996;75:971-82.
38. Besbas N, Erbay A, Saatci U, Ozdemir S, Bakkaloglu A, Ozen S, et al. Thrombomodulin, tissue plasminogen activator and plasminogen activator inhibitor-1 in Henoch-Schoenlein purpura. Clin Exp Rheumatol 1998;16:95-8.
39. Odhama S, Takano S, Miyake S, Kubota T, Sato K, Aoki N. Plasma thrombomodulin as a marker of vascular injuries in collagen vascular diseases. Am J Clin Pathol 1994;101:109-13.
40. Takaya M, Ichikawa Y, Kobayashi N, Kawada T, Shimizu H, Uchiyama M, et al. Serum thrombomodulin and anticardiolipin antibodies in patients with systemic lupus erythematosus reports where it was found increased. Clin Exp Rheumatol 1991;9:495-9.
41. Soma Y, Takehara K, Sato S, Ishibashi Y. Increase in plasma thrombomodulin in patients with systemic sclerosis. J Rheumatol 1993;10:1444-5.
42. Mercie P, Seigneur M, Conri C. Plasma thrombomodulin as a marker of vascular damage in systemic sclerosis. J Rheumatol 1995;22:1440-1.
43. Mizutani H, Hayashi T, Nouchi N, Inachi S, Suzuki K, Shimizu M. Increased endothelial and epidermal thrombomodulin expression and plasma thrombomodulin level in progressive systemic sclerosis. Acta Med Okayama 1996;50:293-7.
44. Oohira A, Wight TN, Bornstein P. Sulphated proteoglycans synthetized by vascular endothelial cells in culture. J Biol Chem 1983;258:2014-21.
45. Rix DA, Douglas MS, Talbot D, Dark JH, Kirby JA. Role of glycosaminoglycans in the regulation of the immunogenicity of human vascular endothelial cells. Clin Exp Immunol 1996;104:60-5.
46. Mascia F, Paoletti P, Mameli G, Mamusa AM, Cirillo R, Marongiu F. Dermatansulphate, heparin cofactor II and F1+2 peptide in non-insulin-dependent diabetes mellitus. Thromb Res 2000;97:263-5.
47. Westergren-Thorsson G, Coster L, Akesson A, Wollheim FA. Altered dermatan sulphate proteoglycan synthesis in fibroblast cultures established from skin of patients with systemic sclerosis. J Rheumatol 1996;23:1398-406.
48. Kuroda K, Shinkai H. Decorin and glycosaminoglycans synthesis in skin fibroblasts from patients with systemic sclerosis. Arch Dermatol Res 1997;289:481-5.
49. Hansen C, Otto E, Kuhlemann K, Forster G, Kahaly GJ. Glycosaminoglicans in autoimmunity. Clin Exp Rheumatol 1996;14(suppl 15):s59-s67.
50. Penc SF, Pomahac B, Eriksson E, Detmar M, Gallo RL. Dermatan sulphate activates nuclear factor kB and induces endothelial and circulating intercellular adhesion molecule-1. J Clin Invest 1999;103:1329-35.
51. Lau CS, Mclaren M, Mckay I, Belch JJ. Baseline plasma fibrinolysis and its correlation with clinical manifestations in patients with Raynaud's phenomenon. Ann Rheum Dis 1993; 52:443-8.
52. Valentini G. Coagulation and fibrinolysis in systemic sclerosis. Presented at the International Conference on Systemic Sclerosis, Montecatini Terme, Italy, March 22-26, 1998. Clin Exp Rheumatol 1998;16:362 (abstr 30).
53. Fritzler MJ, Hart DA, Wilson D, Garcia-De La Torre I, Vazquez-Del Mercado M, Senecal JL, et al. Antibodies to fibrin bound tissue type plasminogen activator in systemic sclerosis. J Rheumatol 1995;22:1688-93.
54. Del Rosso M, Fibbi G, Matucci Cerinic M. The urokinase-type plasminogen activator system and inflammatory joint diseases. Clin Exp Rheumatol 1999;17:485-92.
55. Leeuwenberg JF, Smeets EF, Neefjes JJ, Shaffer MA, Cinek T, Ahern TJ, et al. E selectin and intercellular adhesion molecole 1 are released by activated human endothelial cells in vitro. Immunology 1992;77:543-9.
56. Gruschwitz MS, Hornestein OP, von den Driesch P. Correlation of soluble adhesion molecules in the peripheral blood of sclerodermia patients with their in situ expression and with diesease activity. Arthritis Rheum 1995;38:184-9.
57. Denton CP, Bickerstaff MC, Shiwen X, Carulli MT, Haskard DO, Black CM. Serial circulating adhesion molecole levels reflect disease severity in systemic sclerosis. Br J Rheumatol 1995;34:1048-54.
58. Blann AD, Herrick A, Jayson MIV. Altered levels of solubile adhesion molecules in rheumatoid arthritis, vasculitis and systemic sclerosis. Br J Rheumatol 1995;34:814-19.
59. Ihn H, Sato S, Fujimoto M, Takehara K, Tamaki K. Increased serum levels of solubile vascular cell adhesion molecole 1 and E selectin in patients with systemic sclerosis. Br J Rheumatol 1998;37:1188-92.
60. Veale DJ, Kirk G, McLaren M, Belch JJF. Clinical implications of solubile intercellular adehesion molecole 1 levels in systemic sclerosis. Br J Rheumatol 1998;37:1227-8.
61. Andersen GN, Caidahl K, Kazzam E, Petersson AS, Waldenstrom A, Mincheva-Nilsson L, et al. Correlation between increased nitric oxide production and markers of endothelial activation in systemic sclerosis. Findings with the solubile adhesion molecole E selectin, intercellular adhesion molecole 1 and vascular adhesion molecole 1. Arthritis Rheum 2000;43:1085-93.
62. Denton CP, Howell K, Stratton RJ, Black CM. Long-term low molecular weight heparin therapy for severe Raynaud's phenomenon: a pilot study. Clin Exp Rheumatol 2000;18:499-502.
63. Beguin S, Kumar R, Keularts I, Selgsohn U, Coller BS, Hemker HC. Fibrin-dependent platelet procoagulant activity requires GPIb receptors and von Willebrand factor. Blood 1999;93:564-70.
64. Mannucci PM, Lombardi R, Lattuada, Perticucci E, Valsecchi R, Remuzzi G. Supranormal von Willebrand factor multimers in scleroderma. Blood 1989;73:1586-91.
65. Marasini B, Cugno M, Bassani C, Stanzani M, Bottasso B, Agostoni A. tPA and vWF plasma levels as markers of endothelial involvement in patients with Raynaud's phenomenon. Int J Microcirc Clin Exp 1992;11:375-82.
66. Scheja A, Akesson A, Geborek P, Wildt M, Wollheim CB, Wollheim FA et al. Von Willebrand factor propeptide as a marker of disease activity in systemic sclerosis (scleroderma). Arthritis Res 2001;3:178-82.
67. Jarrett PEM, Moreland M, Browse NL. Treatment of Raynaud's phenomenon by fibrinolytic enhancement. Br Med J 1978;2:523-5.
68. Jayson MIV, Holland CD, Keegan A, Illingworth K, Taylor L. A controlled study of stanozolol in primary Raynaud's phenomenon and systemic sclerosis. Ann Rheum Dis 1991;50:41-7.
69. Wilson D, Edworthy SM, Hart DA, Fritzler MJ. The safety and efficacy of low dose plasminogen activator in the treatment of systemic sclerosis. J Dermatol 1995;22:637-42.
70. Klimiuk PS, Kay EA, Illingworth KJ, Gush RJ, Taylor LJ, Baker R, et al. A double blind placebo controlled trial of recombinant tissue plasminogen activator in the treatment of digital ischemia in systemic sclerosis. J Rheumatol 1992;19:716-20.
71. Lakshminarayanan S, Maestrello SJ, Vazquez Abad D, Waterman JR. Treatment of severe Raynaud's phenomenon and ischemic ulcerations with tissue plasminogen activator (letter). Clin Exp Rheumatol 1999;17:260.
72. Gluszko P, Undas A, Kwasny B, Musial J, Szczeklik A. Treatment with interferon gamma enhances fibrinolysis in systemic sclerosis. Thromb Res 1998;91:203-7.
73. Keller J, Kaltenecker A, Schricker KT, Neidhart B, Hornstein OP. Inhibition of platelet aggregation by a new stable prostacyclin introduced in therapy of patients with progressive scleroderma. Arch Dermatol Res 1985;277:323-5.
74. Candela M, Pansoni A, Jannino L, Menditto VG, Natalini M, Ravaglia F, Da Lio L, Scorza R, Gabrielli A, Danieli G. Coagulative modifications in patients with systemic sclerosis treated with iloprost or nifedipine. Ann Ital Med Int 2001;16:170-4.